Varaico: Literature-Extracted Genetic Variants

Gene:TMED7
Variant:p.F63I
Back to variants list

TMED7

NM_181836.6:p.F63I

Associated Papers

Cell cycle duration determines oncogenic transformation capacity.

Chen D et al.

Nature, 2025

Distinct outcomes from targeted perturbations of the multi-subunit SCFSkp2 E3 ubiquitin ligase in blocking Trp53/Rb1-null prostate tumorigenesis.

Xue Y et al.

Communications Biology, 2025

The Mitotic Checkpoint Complex controls the association of Cdc20 regulatory protein with the ubiquitin ligase APC/C in mitosis.

Sitry-Shevah D et al.

Proceedings of the National Academy of Sciences of the United States of America, 2024

Comprehensive single cell transcriptomics analysis of murine osteosarcoma uncovers Skp2 function in metastasis, genomic instability and immune activation and reveals additional target pathways.

Ferrena A et al.

Biorxiv : the Preprint Server for Biology, 2024

Targeted inhibition of SCFSKP2 confers anti-tumor activities resulting in a survival benefit in osteosarcoma.

Wang J et al.

Oncogene, 2024

Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.

Gupta P et al.

British Journal of Cancer, 2022

Regulation of p27 (Kip1) by Ubiquitin E3 Ligase RNF6.

Deshmukh D et al.

Pharmaceutics, 2022

A cancer-associated CDKN1B mutation induces p27 phosphorylation on a novel residue: a new mechanism for tumor suppressor loss-of-function.

Bencivenga D et al.

Molecular Oncology, 2021

Targeted Inhibition of the E3 Ligase SCFSkp2/Cks1 Has Antitumor Activity in RB1-Deficient Human and Mouse Small-Cell Lung Cancer.

Zhao H et al.

Cancer Research, 2020

Caspases uncouple p27(Kip1) from cell cycle regulated degradation and abolish its ability to stimulate cell migration and invasion.

Podmirseg SR et al.

Oncogene, 2016

Connexin Controls Cell-Cycle Exit and Cell Differentiation by Directly Promoting Cytosolic Localization and Degradation of E3 Ligase Skp2.

Shi Q et al.

Developmental Cell, 2015

Skp2-macroH2A1-CDK8 axis orchestrates G2/M transition and tumorigenesis.

Xu D et al.

Nature Communications, 2015

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein.

Agarwal A et al.

Blood, 2014

Rb suppresses human cone-precursor-derived retinoblastoma tumours.

Xu XL et al.

Nature, 2014

PCTAIRE1 phosphorylates p27 and regulates mitosis in cancer cells.

Yanagi T et al.

Cancer Research, 2014

Skp2 suppresses apoptosis in Rb1-deficient tumours by limiting E2F1 activity.

Lu Z et al.

Nature Communications, 2014

Apolipoprotein E-mediated cell cycle arrest linked to p27 and the Cox2-dependent repression of miR221/222.

Kothapalli D et al.

Atherosclerosis, 2013

Artemis interacts with the Cul4A-DDB1DDB2 ubiquitin E3 ligase and regulates degradation of the CDK inhibitor p27.

Yan Y et al.

Cell Cycle (georgetown, Tex.), 2011

An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.

Ceccarelli DF et al.

Cell, 2011

Cyclins, Cdks, E2f, Skp2, and more at the first international RB Tumor Suppressor Meeting.

Bremner R et al.

Cancer Research, 2010

Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/- mice.

Wang H et al.

Nature Genetics, 2010

Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB.

Lin HK et al.

Nature Cell Biology, 2009

A functional link between Wnt signaling and SKP2-independent p27 turnover in mammary tumors.

Miranda-Carboni GA et al.

Genes & Development, 2008

Differential regulation of the cyclin-dependent kinase inhibitors p21(Cip1) and p27(Kip1) by phosphorylation directed by the cyclin encoded by Murine Herpesvirus 68.

Yarmishyn A et al.

Experimental Cell Research, 2008

A mechanism misregulating p27 in tumors discovered in a functional genomic screen.

Garrett-Engele CM et al.

Plos Genetics, 2007

p27Kip1 localization depends on the tumor suppressor protein tuberin.

Rosner M et al.

Human Molecular Genetics, 2007

Substrate recognition and ubiquitination of SCFSkp2/Cks1 ubiquitin-protein isopeptide ligase.

Xu S et al.

The Journal of Biological Chemistry, 2007

Mutations of phosphorylation sites Ser10 and Thr187 of p27Kip1 abolish cytoplasmic redistribution but do not abrogate G0/1 phase arrest in the HepG2 cell line.

Guan X et al.

Biochemical and Biophysical Research Communications, 2006

Oncogenic Ras blocks transforming growth factor-beta-induced cell-cycle arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway.

Schepers H et al.

Experimental Hematology, 2005

Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2.

Rosner M et al.

The Journal of Biological Chemistry, 2004

The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk/dyrk1B kinase.

Deng X et al.

The Journal of Biological Chemistry, 2004

CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear export signal and links p27 export and proteolysis.

Connor MK et al.

Molecular Biology of the Cell, 2003

PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization.

Shin I et al.

Nature Medicine, 2002

Jab1 co-activation of c-Jun is abrogated by the serine 10-phosphorylated form of p27Kip1.

Chopra S et al.

The Journal of Biological Chemistry, 2002

Transfection of p27(Kip1) threonine residue 187 mutant type gene, which is not influenced by ubiquitin-mediated degradation, induces cell cycle arrest in oral squamous cell carcinoma cells.

Kudo Y et al.

Oncology, 2002

p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite for its proteolysis.

Rodier G et al.

The Embo Journal, 2001

A mouse knock-in model exposes sequential proteolytic pathways that regulate p27Kip1 in G1 and S phase.

Malek NP et al.

Nature, 2001

SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Carrano AC et al.

Nature Cell Biology, 1999

Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation.

Montagnoli A et al.

Genes & Development, 1999

Synthetic lethality-based targets for discovery of new cancer therapeutics.

Weidle UH et al.

Cancer Genomics & Proteomics, 0

Select a paper to view details
UCSC Genome Browser·Imprint·Privacy·Terms·Feedback·Email Updates·

Regarding the variants extracted from papers and shown text snippets from research papers, the following holds: "Some rights reserved. This work permits non-commercial use, distribution and reproduction in any medium, provided the original author and source are credited."